✦ LIBER ✦

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine

✍ Scribed by S. MANOLAKOPOULOS; S. BETHANIS; S. KOUTSOUNAS; J. GOULIS; J. VLACHOGIANNAKOS; E. CHRISTIAS; A. SAVERIADIS; C. PAVLIDIS; C. TRIANTOS; A. CHRISTIDOU; G. PAPATHEODORIDIS; D. KARAMANOLIS; D. TZOURMAKLIOTIS

Book ID: 108605196
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 158 KB
Volume: 27
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2007.03567.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adefovir dipivoxil added to ongoing lami

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B

✍ T. Vassiliadis; N. Nikolaidis; O. Giouleme; K. Tziomalos; N. Grammatikos; K. Pat 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Adefovir rapidly suppresses hepatitis B

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine

✍ Pietro Lampertico; Mauro Viganò; Elena Manenti; Massimo Iavarone; Giovanna Lungh 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

Progression of hepatitis B in patients with lamivudine-resistant strains is slowed down by adefovir dipivoxil (ADV). Whether the time point of ADV administration (genotypic vs. phenotypic resistance) influences the outcome of therapy is unknown. We compared the outcome of ADV therapy in hepatitis B

Adefovir dipivoxil for wait-listed and p

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

✍ Eugene Schiff; Ching-Lung Lai; Stephanos Hadziyannis; Peter Neuhaus; Norah Terra 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

Wait-listed (n ϭ 226) or post-liver transplantation (n ϭ 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable

Clinical course and predictive factors o

Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients

✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Factors contributing to antiviral effect

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B

✍ Nao Kurashige; Naoki Hiramatsu; Kazuyoshi Ohkawa; Takayuki Yakushijin; Shinichi 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 321 KB

Mutations associated with the therapeuti

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis

✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated